Replies to post #240868 on Biotech Values

[semi_infinite]

It appears no one is close to FC for HBV. JNJ and ARWR seem quite happy with their results yet not close to FV for most. Perhaps the best one can hope for is to improve upon current SoC. Tweaking old molecules would be one approach.

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-collaborator-presents-phase-2b-clinical-data-reef-1